<DOC>
	<DOCNO>NCT02999854</DOCNO>
	<brief_summary>The primary objective study compare safety efficacy haploidentical T-cell deplete HSCT adjunctive treatment ATIR101 versus haploidentical T cell replete HSCT post-transplant administration high dose cyclophosphamide ( PTCy ) patient hematologic malignancy . An additional objective study compare effect two treatment quality life .</brief_summary>
	<brief_title>Safety Efficacy ATIR101 Adjunctive Treatment Blood Stem Cell Transplantation From Haploidentical Family Donor Compared Post-transplant Cyclophosphamide Patients With Blood Cancer</brief_title>
	<detailed_description>Study CR-AIR-009 Phase III randomize control multicenter open-label study compare two parallel group . After sign informed consent , total 195 patient randomize 1:1 fashion receive either T-cell deplete hematopoietic stem cell transplantation ( HSCT ; CD34 selection ) relate , haploidentical donor , follow ATIR101 infusion , T-cell replete HSCT , follow high dose post-transplant cyclophosphamide ( PTCy ) . Randomization use minimization balance treatment group respect underlying disease ( AML , ALL , MDS ) , Disease Risk Index ( DRI ; intermediate risk , high risk , high risk ) center . A stochastic treatment allocation procedure use treatment assignment random patient enter study . Patients randomized ATIR101 group receive single ATIR101 dose 2×10E6 viable T-cells/kg 28 32 day HSCT . Patients randomized PTCy group receive cyclophosphamide 50 mg/kg/day 3 4/5 day HSCT . All patient follow 24 month post HSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Any following hematologic malignancy : Acute myeloid leukemia ( AML ) first cytomorphological remission Disease Risk Index ( DRI ) intermediate , second high cytomorphological remission Acute lymphoblastic leukemia ( ALL ) first high remission Myelodysplastic syndrome ( MDS ) : transfusiondependent ( require least one transfusion per month ) , intermediate high Revised International Prognostic Scoring System ( IPSSR ) risk group Clinical justification allogeneic stem cell transplantation suitable HLA match sibling unrelated donor unavailable timely manner . An unrelated donor search require patient eligible clinical situation dictate urgent transplantation . Clinical urgency define 68 week referral transplant center low likelihood find match unrelated donor Availability relate haploidentical donor ≥ 4/8 &lt; 8/8 , ≥ 5/10 &lt; 10/10 match HLAA , B , C , DRB1 , and/or DQB1 locus , determine high resolution human leukocyte antigen ( HLA ) type Karnofsky Performance Status ( KPS ) ≥ 70 % Male female , age ≥ 18 year ≤ 70 year . Patients age ≥ 65 year must Sorror score ≤ 3 Availability donor age ≥ 16 year ≤ 75 year eligible accord local requirement regulation For female childbearing potential sexually active male sexual contact female childbearing potential : use reliable method contraception study participation Given write informed consent ( patient donor ) Availability suitable fully match relate unrelated donor donor search Prior allogeneic hematopoietic stem cell transplantation Diffusing capacity carbon monoxide ( DLCO ) &lt; 50 % predict Left ventricular ejection fraction &lt; 50 % ( evaluate echocardiogram MUGA ) aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 × upper limit normal ( CTCAE grade 2 ) Bilirubin &gt; 1.5 × upper limit normal ( CTCAE grade 2 ) Creatinine clearance &lt; 50 ml/min ( calculate measure ) Positive pregnancy test breastfeed patient donor ( woman childbearing age ) Estimated probability survive less 3 month Known allergy component ATIR101 ( e.g. , dimethyl sulfoxide ) Known hypersensitivity cyclophosphamide metabolites Known presence HLA antibody nonshared donor haplotype Positive human immunodeficiency virus ( HIV ) test Positive CMV test patient negative cytomegalovirus ( CMV ) test donor Positive viral test donor HIV1 , HIV2 , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , Treponema pallidum , human Tlymphotropic virus ( HTLV ) 1 ( test ) , HTLV2 ( test ) , West Nile virus ( WNV ; test ) , Zika virus ( test ) Any condition , opinion investigator , make patient donor ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Haploidentical stem cell transplantation</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>Immune reconstitution</keyword>
	<keyword>Alloreactive T-cells</keyword>
	<keyword>Photodynamic treatment</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Transplant-related mortality</keyword>
	<keyword>Overall survival</keyword>
	<keyword>GRFS</keyword>
	<keyword>GVHD</keyword>
</DOC>